1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

Slides:



Advertisements
Similar presentations
‘Arthritis’ nomenclature in the daily practice Luc De Clercq, MD.
Advertisements

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.
Dr. Zhao TCM help Rheumatoid Arthritis. What is Rheumatoid Arthritis (RA)? RA is an autoimmune disorder inflammation of the lining of the joints. The body.
Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.
GOOD MEWS, BAD MEWS Using simulated learning to increase confidence and decision making skills when managing medical emergencies – third year nursing students.
Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,
Cathryn Caton, MD, MS May 23, 2013 Medical University of South Carolina.
Rheumatoid Arthritis: Modern Management of an Ancient Disease Dr Chandini Rao Consultant Rheumatologist RHEUMATOLOGY IN THE 21 st CENTURY.
Exercise in Ankylosing Spondylitis Prof. Pál Géher MD.
GRAPPA Guidelines for PsA: Considerations
Psoriatic arthritis – definition and classification criteria Philip Helliwell Senior Lecturer in Rheumatology University of Leeds.
Rheumatoid Arthritis Anila Malik GPVTS. Aims To cover the following: What is RA? Diagnostic criteria and clinical features Rheumatoid Factor Investigations.
North American Neuromodulation Society Meeting 2012 Harnessing the Inflammatory Reflex: Using Neuromodulation as a Novel Approach to Treat Chronic Inflammatory.
Non-Radiographic Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes in a National Database Sherry Rohekar 1, Robert D.
PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.
OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.
EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
Rheumatology teaching session GP ST2 year 8/9/10.
Outcome measures for balneotherapy NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY Budapest, Hungary Dr. LÁSZLÓ HODINKA Recommendations.
Inflammatory Disorders Inflammation of joints Include Rheumatoid Arthritis Ankylosing spondylitis Osteomyelitis Bursitis Polymyositis.
Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
Please enjoy the show…….. By : Ashlee Kolkow What is RA? Most serious form of arthritis, leading to severe crippling Autoimmune disorder Chronic inflammation.
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.
The Value of Reference Case Methods for Resource Allocation Decision Making Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics.
IMAGING NEURAL CORRELATES OF FATIGUE & PAIN IN PATIENTS WITH RA TREATED WITH TNF INHIBITORS FARHAN BARI SPR RHEUMATOLOGY WARN CONFERENCE 22 ND MAY 2014.
3 STUDENT ASSESSMENT DEPARTMENT
This presentation is a case report of a 62-year-old female Indian, clinically diagnosed with Rheumatoid Arthritis at the age of 12.
Rheumatology What we do & How to help Ronan Mullan.
Introduction to collagen-vascular diseases. Definition: Rheumatologic (or Rheumatic) Disease: diseases characterized by pain and inflammation in joints.
Rheumatology Mastery in Ankylosing Spondylitis
Identifying Early Inflammatory Arthritis
AS – the facts! Andrew Keat.
Chief investigator- Dr. Kripasindhu Gantait, Associate Professor
Dr Stéphanie POUMEAUD-LAFARGE A local survey in 2014
Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.
B-CELL SUBSETS DIFFERENCES IN INFLAMMATORY RHEUMATIC DISEASES
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy 
Sidra Hussain, Priyanka Sivakumaran Coziana Ciurtin
IL-17 Inhibitors in the Management of Psoriatic Disease
Disease Activity Assessment Across the RA Continuum
Precision Management of RA and Comorbidities
Is RA Treatment Addressing the Real Needs of Patients?
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy 
Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Updates in RA, PsA, and Biosimilars
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Univariate predictors of (A) ASDAS ID (<1
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Figure 1 Patterns of joint and organ involvement in rheumatic disease
Two types of scoring systems used to measure pain.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.
DAS28-CRP cut-off values corresponding to the DAS28-ESR cut-off values for remission, LDA and HDA, average of three statistical approaches. DAS28-CRP cut-off.
Clinical response in patients with early and established RA at month 24. *p
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Dr Sarah Levy Consultant Rheumatologist CUH
Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.
Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
(A) JIA-ACR30/50/70/90 response rates by visit in part 1.
Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.
Multivariable model of adjusted
Presentation transcript:

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012

2 Disease Specific RA – DAS28,ACR 20/50/70 Psoriatic Arthritis – PSARC Ankylosing Spondylitis – BSADAI, BASFI, BASMI.

3 The DAS 28 What is it? Why is it done? What the results mean? Limitations.

4 What is it? Measure of disease activity. Includes the number of swollen and tender joints, blood results, how you feel. Calculated – gives your arthritis a score.

5 Why is it done? Assess response to treatment. Assess eligibility for biologic treatments. Documents your progress. Outcome measure, provides evidence. Standardised assessment - used in research.

6 How is it Done Dr / Nurse assess joints (28 in total). Blood test ESR / CRP = measures of inflammation. Global Score – how active your arthritis is on a 100mm line (0 – 100).

7 What do we mean by ‘Active’ NOT How active you are. BUT How bad is your arthritis at present? How inflamed are your joints? and how you feel? (Flare ups). Pain measured separately to ‘activity’.

8 What do the results mean? Less than 2.6 = Remission. 2.6 – 3.2 = Low Disease Activity. More than 3.2 = may indicate a need to change treatment. More than 5.1 = High Disease Activity.

9 Limitations. Subjective – relies on how individual feels and their understanding what is being measured / asked. Differences between early and advanced arthritis. False highs and lows – interpretation needs clinical judgement. Doesn’t include feet. Not the perfect tool.

10 Considerations. DAS assessment only a small part of your overall assessment. Needs clinical interpretation. Requires some skill and knowledge and standardisation within Rheumatology departments.

11 Thank you. Any Questions??